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NON-ALCOHOLIC FATTY LIVER DISEASE
Unselective screening for liver diseasemay not be cost
effective
Michael Marks clinical research fellow 1, Andrew Chadwick registrar 2
1Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK; 2Intensive Care Medicine, Oxford University Hospitals
NHS Trust, Oxford, UK
Sattar and colleagues review the epidemiology, manifestations,
and management of non-alcoholic fatty liver disease.1 They
recommend considering screening for other liver conditions
such as chronic viral hepatitis, autoimmune liver disease,
haemochromatosis, and drug induced liver injury. The value
and cost implications of such screening in people with abnormal
results in liver function tests are unclear.
A prospective study in 11 primary care practices of 1290 people
with abnormal liver function results established a diagnosis in
less than 5% of cases.2 Only 17 (1.3%) people were diagnosed
with a condition that needed specific treatment, with most (13)
having viral hepatitis.
In a study of 1118 patients in primary care, non-alcoholic fatty
liver disease and alcohol related liver disease were the most
common causes of abnormal liver function tests (26.4% and
25.3%, respectively).3 Autoimmune and inherited metabolic
conditions accounted for only 1% each.
We reviewed clinical notes, imaging results, and test results for
338 consecutive patients with abnormal liver function results
who presented to a tertiary care hospital over one year. We
found that alcoholic liver disease was the most common
underlying diagnosis (22%). A thorough history and
ultrasonography had the highest diagnostic yield, followed by
testing for chronic viral hepatitis, which reached a diagnosis in
14% of patients. The cost per diagnosis varied substantially
between tests (table⇓). The yield of screening for metabolic and
autoimmune causes of liver disease was minimal.
Unselective diagnostic testing places a large financial burden
on the NHS,4 often for limited diagnostic yield. Further
prospective studies comparing different diagnostic strategies
for patients with abnormal liver function tests are urgently
needed to inform clinical practice.
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Table
Table 1| Diagnostic yield of investigations for abnormal liver function test results
Cost per diagnosis (£)Diagnostic yield (%)Investigation
N/A40History
15830Ultrasonography
8573Hepatitis A screening
10444Hepatitis B screening
2657Hepatitis C screening
27961Autoimmune screen
N/A0Metabolic tests
£1=€1.26=$1.66. N/A=not applicable.
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